In a major shift, pharmaceutical giant Gilead Sciences will begin airing television ads for PrEP, its HIV prevention medication. The company said the ads, which will start in June and run through August, are “designed to encourage candid conversations around sexual health and promote public awareness of HIV prevention.”
PrEP, or pre-exposure prophylaxis, involves taking a daily pill to prevent HIV transmission. Major clinical trials have shown that PrEP — also known by its brand name, Truvada — is safe and effective at preventing HIV if taken daily. The pill is also recommended by the Centers for Disease Control and Prevention for at-risk groups.
Since the Food and Drug Administration (FDA) approved Truvada for HIV prevention in 2012, Gilead has leaned on public health agencies to promote the drug. New York City has for years placed advertisements on subways and buses to promote PrEP, and the District of Columbia’s health department aired its own racy HIV PrEP television ad earlier this year.
Popular dating apps could soon help stop the spread of record high STD infections among their users.
Grindr and other primarily gay dating apps are exploring ways to add the ability for people who test positive for an STD to notify partners using the app, Mashable has learned in multiple interviews with public health experts.
According to Dr. Heidi Bauer, the chief of STD control at the California Department of Health, and Dan Wohlfeiler, director of the health consortium Building Healthy Online Communities(BHOC), STD partner notification messages are currently under consideration by several different app-makers, including Grindr, with one possibility already in the design and piloting phase.
Last September, on National Gay Men’s HIV/AIDS Awareness Day, the Center for Disease Control (CDC) declared that men with HIV who have an undetectable viral load—levels of HIV in the blood that are below the threshold of detection—are unable to transmit HIV to their partners. This is often summarized with the phrase Undetectable = Untransmittable or U = U.
The CDC came to this conclusion after evaluating three studies that included thousands of couples engaging in unprotected sexual acts in which one partner was HIV-positive with an undetectable viral load, and the other was HIV-negative and not on pre-exposure prophylaxis (PrEP).
“No HIV transmissions to an HIV-negative partner were observed when the HIV-positive person was virally suppressed,” the CDC reported.
When levels are this low, the virus is so suppressed that it’s impossible to pass on the virus to a partner sexually. Consequently, HIV treatment is now being used as a form of prevention, commonly referred to a TasP (Treatment as Prevention).
It’s been over 30 years since the inception of the virus, and still, there is so much shaming and stigma surrounding people living with HIV. This in large part due to misinformation and fear of contracting the virus. That’s what led Drs. Jonathon Rendina and Jeffrey Parsons of Hunter College to explore whether gay, bisexual, and other men who have sex with men actually believe that undetectable = untransmittable.
After the AIDS epidemic there was “a sense that nobody could be trusted that had negative effects on guys with and without HIV,” Dr. Rendina tells Newnownext.
The incidence rate of syphilis in people with HIV increased through 2015, according to new research published in Clinical Infectious Diseases.
Since 2000, the incidence of syphilis has increased among gay, bisexual, and other men who have sex with men (MSM) in the United States. This represents an ongoing sexual risk, and temporal trends and associated risk factors for newly diagnosed syphilis infections among people with HIV were therefore investigated.
Data from HIV Outpatient Study cohort participants visiting 10 clinics in the United States from 1999 to 2015 were analyzed. A total of 6888 participants with HIV were included, and 641 had one or more new syphilis diagnoses during a median follow period of 5.2 years. Participants were mostly male, age 31 to 50 years (78%), and the majority were MSM (56%).
Since PrEP is one of the newer HIV prevention tools, understanding more about who is using it is important to better tailoring HIV prevention efforts at the national, state, and community levels. PrEP, or pre-exposure prophylaxis, is when people at high risk for HIV take HIV medicine daily to lower their chances of getting infected with HIV. AIDSVu has released the first-ever publicly available data and interactive maps of PrEP use by state from 2012 through 2016, stratified by sex and age.
The new maps from AIDSVu show more than 77,000 people were prescribed PrEP in 2016, with an average 73 percent increase year over year in persons using PrEP across the U.S. from 2012 – when the drug TDF/FTC was approved by the FDA for use as PrEP – to 2016. However, approximately 1.1 million people in the U.S. are at substantial risk for HIV exposure and could benefit from PrEP, according to analysis presented by the Centers for Disease Control and Prevention (CDC) at CROI 2018 earlier this year.
The data presented on AIDSVu reveal that the growth and distribution of PrEP use has been inconsistent across different sexes, age groups, and geographic regions. For example, the Southern U.S. accounted for more than half (52 percent) of all new HIV diagnoses in 2016 but represented only 30 percent of all PrEP users in 2016. That same year, women comprised 19 percent of all new HIV diagnoses but made up only seven percent of all PrEP users.